Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Jpn J Clin Oncol. 2011 May;41(5):609-16. doi: 10.1093/jjco/hyr022. Epub 2011 Mar 16.
To investigate the treatment results of intracranial meningiomas treated with hypofractionated stereotactic radiation therapy in three to five fractions.
Thirty-one patients (32 lesions) with intracranial meningioma were treated with hypofractionated stereotactic radiation therapy in three to five fractions using CyberKnife. Fifteen lesions were diagnosed as Grade I (World Health Organization classification) by surgical resection and 17 lesions were diagnosed as meningioma based on radiological findings. The median follow-up time was 48 months. The median planning target volume was 6.3 cm(3) (range, 1.4-27.1), and the prescribed dose (D90≤) ranged from 21 to 36 Gy (median, 27.8) administrated in three to five fractions.
Five-year overall and progression-free survival rate of all 31 patients with intracranial meningioma was 86 and 83%, respectively. Five-year progression-free rate of all 32 lesions was 87%. Six of the 31 patients (19%) developed marked peritumoral edema, three of whom were asymptomatic and three symptomatic, the latter with late adverse effects of more than or equal to Grade 3. The mean planning target volume of the six lesions with marked peritumoral edema was 15.6 cm(3), and for the remaining 26 lesions without marked peritumoral edema was 7.1 cm(3) (P = 0.004). The threshold diameter of 2.56 cm for meningioma was calculated from the planning target volume (11 cm(3)) and was used as marker of developing peritumoral edema (P = 0.003).
Tumor volume is a significant indicative factor for peritumoral edema in intracranial meningioma treated with hypofractionated stereotactic radiation therapy in three to five factions.
研究采用 3-5 次分割的立体定向适形放射治疗颅内脑膜瘤的治疗效果。
31 例(32 个病灶)颅内脑膜瘤患者采用 CyberKnife 行 3-5 次分割立体定向适形放射治疗。15 个病灶经手术切除后诊断为Ⅰ级(世界卫生组织分级),17 个病灶根据影像学表现诊断为脑膜瘤。中位随访时间为 48 个月。中位计划靶区体积为 6.3cm³(范围:1.4-27.1cm³),处方剂量(D90≤)为 21-36Gy(中位剂量 27.8Gy),分割 3-5 次。
31 例颅内脑膜瘤患者的 5 年总生存率和无进展生存率分别为 86%和 83%。32 个病灶的 5 年无进展生存率为 87%。31 例患者中有 6 例(19%)出现明显的瘤周水肿,其中 3 例无症状,3 例有症状,后者有≥3 级的迟发性不良反应。6 例瘤周水肿明显的病灶的平均计划靶区体积为 15.6cm³,而其余 26 例无明显瘤周水肿的病灶的计划靶区体积为 7.1cm³(P=0.004)。从计划靶区体积(11cm³)计算出脑膜瘤的阈值直径为 2.56cm,并将其作为发生瘤周水肿的标志物(P=0.003)。
肿瘤体积是采用 3-5 次分割立体定向适形放射治疗颅内脑膜瘤后瘤周水肿的一个重要的提示性因素。